SEATTLE--(BUSINESS WIRE)--Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, surveyed more than 600 adults (age 18-65+) within the United States to assess ...
Rusfertide significantly reduced phlebotomy needs in PV patients, with 76.9% achieving clinical response versus 32.9% in the placebo group. The therapy maintained hematocrit levels below 45% in 62.6% ...
Vitestro, a pioneer in medical robotics advancing automated diagnostic blood collection, today announced the launch of its new corporate website and the release of its first publicly available video.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback